Expert Opinion on Biological Therapy

Article	Citations
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	104
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)	51
Statement of Retraction	49
Bispecific antibodies for the treatment of hemophilia A	47
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry	41
Belimumab for the treatment of pediatric patients with lupus nephritis	39
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?	36
Aflibercept biosimilars – so near, yet so far	33
Bispecific antibodies for immune cell retargeting against cancer	31
Biologic therapies for chronic obstructive pulmonary disease	31
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	30
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	30
The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review	30
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	29
Biological therapies for the treatment of psoriasis in pediatrics	29
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer	27
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	26
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	25
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies	24
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	22
Cell-based therapies for the treatment of sports injuries of the upper limb	22
Elotuzumab in multiple myeloma	21
Biologic insights from single-cell studies of psoriasis and psoriatic arthritis	21
Perceptions of airway gene therapy for cystic fibrosis	21
Steps towards the clinical application of endometrial and menstrual fluid mesenchymal stem cells for the treatment of gynecological disorders	20

Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group	20
Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments’ evidence: a systematic review an	20
Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline)	20
Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis	19
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	18
Analytical similarity assessment of MYL-1402O to reference Bevacizumab	18
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healt	18
Current and Future Options of Haemophilia A Treatments	17
CAR-NK cells: a promising cellular immunotherapy in lymphoma	17
How can clinical safety and efficacy concerns in stem cell therapy for spinal cord injury be overcome?	17
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	16
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	16
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	16
Clinical management and innovation in fracture non-union	15
Emerging therapies for human hearing loss	14
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	14
Current and preclinical treatment options for Merkel cell carcinoma	14
Mosunetuzumab for the treatment of follicular lymphoma	14
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	14
Advancements in biologic therapy in eosinophilic asthma	13
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	13
Clinical updates in mesenchymal stromal cell therapy for osteoarthritis treatment	12
Could siRNA therapeutics change the way we treat dyslipidemia?	12
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	12
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer	12
Antibody drug conjugates for glioblastoma: current progress towards clinical use	12
Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications – an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information throu	12
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy	12
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries	12
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study	11
Biosimilars and access to biologic therapy in immune-mediated diseases	11
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	11
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network	11
Small molecule-regulated switches to provide functional control of CAR T cells within the patient	11
Correction	11
Non-traditional approaches for control of antibiotic resistance	11
Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now?	11
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	10
The endosomal-lysosomal system in ADC design and cancer therapy	10
The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin E and C for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical	10
Biologics for psoriasis: is there any unmet need left?	10
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	10
Treating psoriasis in the elderly: biologics and small molecules	10
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	10
Belimumab patient profile in Spain: evolution during the last decade and future directions	10
Signaling new therapeutic opportunities: cytokines in prostate cancer	10
Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment	10
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	10
Therapeutic monoclonal antibodies for COVID-19 management: an update	10

Muscle invasive bladder cancer: where is the field headed?	10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	10
How should we approach salvage therapy in advanced renal cell carcinoma after first-line immunotherapy combinations?	9
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges	9
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer	9
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease	9
Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis	9
Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease	9
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	9
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	9
Biological therapy in elderly patients with acute myeloid leukemia	9
Long-acting delivery and therapies for neovascular age-related macular degeneration	9
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease	9
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	9
Recommendations for pregnancy in Fanconi anemia	9
Developing combination therapies with biologics in triple-negative breast cancer	9
Adjuvant immunotherapy for locally advanced renal cell carcinoma	9
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents	8
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	8
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing	8
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	8
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	8
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study	8
IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?	8
Survivin as a biological biomarker for diagnosis and therapy	8
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis	8
Epcoritamab in B-cell malignancies: current status and prospects	8
What role can LAG-3-blocking antibodies play in melanoma therapy?	8
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	8
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer	8
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations	8
Cell homing strategy as a promising approach to the vitality of pulp-dentin complexes in endodontic therapy: focus on potential biomaterials	8
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy	8
What’s new and what’s next for gene therapy in Pompe disease?	8
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	8
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	8
Correction	7
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	7
Oncolytic virotherapies for pediatric tumors	7
Antibody-drug conjugates in oncology: insights into Current challenges	7
Experts’ review: the emerging roles of romiplostim in immune thrombocytopenia (ITP)	7
Next-generation CD40 agonists for cancer immunotherapy	7
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	7
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	7
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	7
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors	7
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	7
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	7
The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: a review	7
Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to acceler	7
Correction	7
Recent advances in stem cell therapy for erectile dysfunction: a narrative review	7
Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market	7
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	7
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy	7
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps	6
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	6
Prostate cancer immunotherapy	6
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	6
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	6
Global experience of faricimab in clinical settings - a review	6
The global landscape on interchangeability of biosimilars	6
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions	6
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity	6
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	6
Antibody therapeutics for epithelial ovarian cancer	6
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer	6
Total pancreatectomy with intraportal islet autotransplantation for pancreatic malignancies: a literature overview	6
Pathogenesis-oriented therapy of psoriasis using biologics	6
Eptinezumab for the treatment of migraine	6
Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis	6
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience	6
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	6
Sargramostim in acute radiation syndrome	6
X-linked myotubular myopathy: an untreated treatable disease	6
Gene Therapy for High Grade Glioma: The Clinical Experience	6
Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases	6
Injectable and adhesive hydrogels for dealing with wounds	6
Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method	6
Drawing on collective action theory to foster sustainable biosimilar markets – insights from co-creation workshops with UK and Belgian stakeholders	5

Moving toward personalized approaches in the management of lupus nephritis	5
Ravulizumab for the treatment of myasthenia gravis	5
Biosimilars: A futuristic fast-to-market advice to developers	5
Gene therapy for Leber hereditary optic neuropathy	5
Management of metastatic melanoma with combinations including PD-1 inhibitors	5
Switching CGRP(r) MoAbs in migraine: what evidence?	5
Genetic screening in new onset inflammatory bowel disease during anti-interleukin 17 therapy: unmet needs and call for action	5
Association between cumulative rATG induction doses and kidney graft outcomes and adverse effects in kidney transplant patients: a systematic review and meta-analysis	5
Clinical development of an anti-GPC-1 antibody for the treatment of cancer	5
The Role of Anti-IL-1 Treatment in MIS-C Patients	5
A plain language summary of the pooled safety results of adalimumab-adbm from the VOLTAIRE clinical trials in people with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	5
Biologics in rectal cancer	5
Are monoclonals the way forward to prevent or to treat ventilator-associated pneumonia in the intensive care unit?	5
Treatment of migraine with monoclonal antibodies	5
Hemophilia A gene therapy: current and next-generation approaches	5
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting	4
The landscape of biosimilars in Saudi Arabia: preparing for the next decade	4
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	4
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	4
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	4
Biologic therapy in relapsing polychondritis: navigating between options	4
Emerging treatment landscape of non-muscle invasive bladder cancer	4
Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF)	4
Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis	4
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center	4
Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety	4
Bispecific CAR T-cells for B-cell Malignancies	4
IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents	4
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma	4
Platelet-rich therapies as an emerging platform for regenerative medicine	4
The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission	4
The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis	4
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	4
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis	4
Stem cell therapy for salivary gland regeneration after radiation injury	4
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	4
IBD goes home: from telemedicine to self-administered advanced therapies	4
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	4
Oncolytic virus therapy for malignant gliomas: entering the new era	4
Need for a risk-based control strategy for managing glycosylation profile for biosimilar products	4
Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis	4
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents	4
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces	4
Biological therapy in polymyalgia rheumatica	4
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	4
Genetic modification and preconditioning strategies to enhance functionality of mesenchymal stromal cells: a clinical perspective	4
Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?	3
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	3
Unmet needs in cervical cancer – can biological therapies plug the gap?	3
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	3
Treatment of fibrous dysplasia: focus on denosumab	3
The evolving therapeutic landscape of diabetic retinopathy	3
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer	3
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	3
An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma	3
Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint ‎inhibition with costimulatory and non-checkpoint targeted therapy	3
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?	3
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond	3
An evaluation of mirikizumab for the treatment of ulcerative colitis	3
Near-infrared photoimmunotherapy for the treatment of skin disorders	3
Clinical experience of using biosimilars in Crohn’s disease and their effectiveness	3
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	3
A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers	3
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	3
Biologics for dengue prevention: up-to-date	3
Strategies for extending the half-life of biotherapeutics: successes and complications	3
Correction	3
New frontiers in personalized medicine in psoriasis	3
An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia	3
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	3
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature	3
Rilonacept for the treatment of recurrent pericarditis	3
Recent developments in CD19-targeted therapies for follicular lymphoma	3
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma	3
Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial	3
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in u	3
Lisocabtagene Maraleucel for the treatment of B-cell lymphoma	3
Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study	3
New drugs for the treatment of hereditary angioedema	3
Correction	3
Envafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors	3
Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian countries: a survey study	3
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives	2
Monoclonal antibodies for treatment of cold agglutinin disease	2
The future of interleukin gene therapy in head and neck cancers	2
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa	2
Perispinal etanercept stroke trial design: PESTO and beyond	2
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	2
Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?	2
Luspatercept for β-thalassemia: beyond red blood cell transfusions	2
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	2
Correction	2
Dynamics of biological markets with multiple biosimilar competitors in the United States	2
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art	2
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy	2